Treatment of progressive ovarian cancer with cis-platinum and doxorubicin.
Thirty-two patients with progressive ovarian carcinoma which had not responded to primary therapy were treated with cis-diamminedichloroplatinum (II) (CDDP) (50 mg/m2) and doxorubicin (50 mg/m2) on day 1 as second-line chemotherapy. An overall response rate of 28% was achieved, the mean duration of response being 5 months. These results are not significantly different from results achieved with other agents used in similar circumstances, but in the light of recent experience it is suggested that this combination warrants a trial as first-line therapy.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery
D004317:Doxorubicin; D002945:Cisplatin